Cardiac Involvement in Wilson's Disease
- Conditions
- Wilson's Disease
- Registration Number
- NCT05493605
- Lead Sponsor
- Fondation Ophtalmologique Adolphe de Rothschild
- Brief Summary
Heart damage by copper accumulation has been reported in Wilson's Disease. However, the disease epidemiology is still poorly understood. A number of studies on pediatric populations have not shown any significant cardiac involvement apart from early dysautonomia. This could suggest that the clinical manifestations related to the copper accumulation in the heart appears with the duration of the disease. Case-control studies on adult populations have highlighted various electrocardiographic (ECG) abnormalities more frequent in patients with Wilson's Disease than in healthy volunteers, but all these studies involved small number of patients (maximum 60). The hypothesis is that there is cardiac involvement in Wilson's Disease, requiring screening, follow-up and appropriate support.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- RECRUITING
- Sex
- All
- Target Recruitment
- 150
- Adult patient with Wilson's disease confirmed by a Leipzig score ≥ 4
- Express consent to participate in the study by the patient or legal guardian in the case of patients under guardianship or by the patient assisted by his curator in the case of patients under guardianship
- Member of or beneficiary of a Social Security scheme
- Absolute or relative contraindication to MRI or contrast media
- Pregnant, parturient or breast-feeding women: a urine pregnancy test will be carried out in women of childbearing age
- Patient with hepatic decompensation (Child-Pugh score stage C)
- Patient in neuro-psychiatric decompensation
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- SINGLE_GROUP
- Primary Outcome Measures
Name Time Method Electrocardiogram - Day 0 Day 0 Description of abnormalities (frequency and percentage)
Contrast-enhanced cardiac MRI - Year 3 Year 3 Description of abnormalities (frequency and percentage)
Electrocardiogram - Year 3 Year 3 Description of abnormalities (frequency and percentage)
Transthoracic echocardiography - Day 0 Day 0 Description of abnormalities (frequency and percentage)
Implantable loop recorder or ECG holter recorder- Day 21 Day 21 Description of abnormalities (frequency and percentage) The device will record from Day 0 to Day 21 Implantable loop recorder assessment will be only performed on patients with syncope.
Chest computed tomography scan without contrast - Day 0 Day 0 Percentage of patients with abnormal coronary artery calcium score
Calcium score : The higher the coronary calcium score, the greater the cardiovascular risk. A score of 0 (min) means that no calcium is seen in the heart. A score greater than 300 is a sign of very high to severe disease.Lying and standing blood pressure tests - Year 3 Year 3 Description of abnormalities (frequency and percentage)
Contrast-enhanced cardiac MRI - Day 0 Day 0 Description of abnormalities (frequency and percentage)
Clinical examination - Day 0 Day 0 Description of abnormalities (frequency and percentage)
Blood and urine tests - Day 0 Day 0 Description of abnormalities (frequency and percentage) Blood tests performed : lipid profile, glycosylated hemoglobin (HbA1C), cardiac enzymes (troponin C, NT-proBNP), ultra-sensitive C-reactive protein, sodium level, potassium level, urea and creatinine clearance, TSH, fibrinogen Urine test performed : proteinuria
Lying and standing blood pressure tests - Day 0 Day 0 Description of abnormalities (frequency and percentage)
Transthoracic echocardiography - Year 3 Year 3 Description of abnormalities (frequency and percentage)
Chest computed tomography scan without contrast - Year 3 Year 3 Percentage of patients with abnormal coronary artery calcium score
Calcium score : The higher the coronary calcium score, the greater the cardiovascular risk. A score of 0 (min) means that no calcium is seen in the heart. A score greater than 300 is a sign of very high to severe disease.Clinical examination - Year 3 Year 3 Description of abnormalities (frequency and percentage)
Blood and urine tests - Year 3 Year 3 Description of abnormalities (frequency and percentage) Blood tests performed : lipid profile, glycosylated hemoglobin (HbA1C), cardiac enzymes (troponin C, NT-proBNP), ultra-sensitive C-reactive protein, sodium level, potassium level, urea and creatinine clearance, TSH, fibrinogen Urine test performed : proteinuria
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
Trial Locations
- Locations (1)
Fondation Adolphe de Rothschild
🇫🇷Paris, France
Fondation Adolphe de Rothschild🇫🇷Paris, FranceAurélia PoujoisContact0148036656apoujois@for.paris